Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

INTRODUCTION: The anticyclic citrullinated peptide 2 (anti-CCP2) assay is a generic test for antibodies to citrullinated proteins, among which there is a subset of about 50% with antibodies to citrullinated enolase peptide 1 (CEP-1). The anti-CEP-1 positive subset is strongly associated with the HLA-DRB1 shared epitope and its interaction with smoking. OBJECTIVE: To investigate whether anti-CEP-1 antibodies may be helpful in predicting outcome. METHODS: Anti-CEP-1 and anti-CCP2 antibodies were measured in two prospective cohorts of patients (Karolinska n=272, Norfolk Arthritis Register (NOAR) n=408) with early rheumatoid arthritis (RA). Outcomes measured were C-reactive protein, erythrocyte sedimentation rate, visual analogue scales for pain and global assessment of disease activity, Health Assessment Questionnaire, physician's assessment, swollen and tender joint counts and radiological progression. RESULTS: Anti-CCP2 antibodies were present in 57% and 50%, and anti-CEP-1 in 27% and 24% of the Karolinska and NOAR cohorts, respectively. Importantly, no statistically significant differences in clinical outcomes were demonstrated between the anti-CEP-1-/CCP2+ and the anti-CEP-1+/CCP2+ subsets in either cohort, or in radiological outcomes in the Karolinska cohort. CONCLUSION: Although antibodies to specific citrullinated proteins may have distinct genetic and environmental risk factors, the similarity in clinical phenotype suggests that they share common pathways in the pathogenesis of joint disease in RA.

Original publication

DOI

10.1136/ard.2010.138909

Type

Journal article

Journal

Ann Rheum Dis

Publication Date

06/2011

Volume

70

Pages

1095 - 1098

Keywords

Adult, Aged, Aged, 80 and over, Antirheumatic Agents, Arthritis, Rheumatoid, Autoantibodies, Biomarkers, Biomarkers, Tumor, Blood Sedimentation, C-Reactive Protein, DNA-Binding Proteins, Disease Progression, Female, Humans, Male, Middle Aged, Peptides, Cyclic, Phosphopyruvate Hydratase, Prognosis, Prospective Studies, Radiography, Severity of Illness Index, Tumor Suppressor Proteins